Lantern Pharma Inc. Files Amendment No. 1 to Annual Report for Fiscal Year Ended December 31, 2025

Overview

Lantern Pharma Inc. has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This amendment updates Part III, Items 10 through 14 of the original Form 10-K, which were previously omitted in reliance on General Instruction G(3) and now include information regarding directors, executive officers, corporate governance, executive compensation, security ownership, related party transactions, director independence, and principal accountant fees.

Key Points for Investors

• Annual Report Confirmation: This amendment confirms Lantern Pharma Inc. has filed an annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Lantern Pharma’s common stock trades on The Nasdaq Stock Market under the symbol LTRN.
• Corporate Structure: The company’s board comprises six members, five of whom are deemed independent under Nasdaq rules. This majority independence is crucial for good governance and shareholder confidence.
• Filing Compliance: Lantern Pharma confirms it is not a well-known seasoned issuer and is required to file reports under Section 13 or 15(d). The company has filed all required reports over the preceding 12 months and submitted all Interactive Data Files required by SEC rules.
• Filer Status: The company is a non-accelerated filer and a smaller reporting company, but not an emerging growth company.
• Internal Controls: The amendment states the company did not file a report or attestation regarding management’s assessment of internal control effectiveness under Section 404(b) of Sarbanes-Oxley. This could be relevant for risk assessment.
• Error Correction: No corrections to previously issued financial statements are included in this amendment.
• Forward-Looking Statements: The amendment includes cautionary language about forward-looking statements, highlighting risks and uncertainties, and advises shareholders not to place undue reliance on such statements.

Corporate Governance & Shareholder Communication

• Communication Policy: Lantern Pharma does not have a formal policy for shareholders to send communications to the board, but shareholders may address letters to the corporate secretary, David R. Margrave, for distribution to directors.
• Insider Trading Policy: The company has adopted an Insider Trading Policy filed as an exhibit, promoting compliance with legal and regulatory standards.
• Equity Award Grant Policy: The Compensation Committee reviews and approves equity awards to executive officers, considering material nonpublic information before granting options. Notably, during 2025, no options were granted to named executive officers during periods immediately before or after material nonpublic information disclosures.

Executive Compensation & Option Repricing

• Option Repricing: Options held by Mr. Margrave to purchase 104,400 shares at a weighted average price of \$13.80 were repriced to \$5.04. However, exercises prior to September 19, 2026, will use the original price. This repricing may be seen as favorable to the executive and potentially dilutive to shareholders, depending on future stock performance.
• Board Compensation: Audit Committee Chair receives \$10,000/year; Compensation Committee Chair and Nominating & Corporate Governance Committee Chair receive \$5,000/year; non-executive directors receive \$46,000/year for board service.

Equity Compensation Plans

Security Ownership

• As of the report date, there are approximately 12 holders of record for Lantern Pharma’s common stock.
• Major Shareholders:
  • Biological Mimetics, Inc.: 844,125 shares (7.47% of outstanding shares)
  • Bios Equity Entities: 834,752 shares
  • Other notable holders include various officers and directors, with significant option holdings.
• Option holdings for named executives are substantial, with hundreds of thousands of shares subject to options exercisable within 60 days, but some are subject to vesting conditions.

Related Party Transactions

The report details transactions since January 1, 2024, involving directors, executive officers, or holders of more than 5% of capital stock, where amounts exceeded \$120,000 or 1% of average total assets. Such transactions are monitored for compliance and governance purposes.

Director Independence

Five out of six board members are independent, meeting Nasdaq requirements and supporting shareholder interests.

Principal Accountant Fees

Exhibits and Certifications

• The amendment includes updated certifications by the Principal Executive Officer (Panna Sharma) and Principal Financial Officer (David R. Margrave), confirming accuracy and completeness of disclosures.
• New exhibits include the Insider Trading Policy, Officer Clawback Policy, and certifications pursuant to Sarbanes-Oxley Act sections 302 and 906.

Potential Price-Sensitive Information

• Option Repricing: The repricing of executive options to \$5.04/share from \$13.80/share may impact shareholder value and signal management’s expectations about future stock performance. If executives exercise options at lower prices, dilution may occur, potentially affecting share price.
• Director Independence and Governance: The robust governance structure and majority-independent board may bolster investor confidence.
• Major Shareholders: Concentrated ownership among institutional holders could impact liquidity and market dynamics.
• Audit Fees and Financial Controls: The absence of a Section 404(b) attestation and relatively high comfort letter fees may raise questions about internal controls and financial rigor.
• Forward-Looking Risks: The company notes material risks and uncertainties in its operations, cautioning investors about potential volatility and unpredictability in future results.
• No Financial Statement Corrections: The amendment does not correct prior financial statements, which may reassure shareholders about past reporting accuracy.

Conclusion

Lantern Pharma’s Amendment No. 1 to its 2025 Annual Report provides critical updates on governance, compensation, equity awards, and related party transactions. Investors should pay close attention to executive option repricing, board independence, and major shareholder dynamics, as these factors can significantly influence share value and market perception. The company’s ongoing compliance and robust governance are positives, while the option repricing and audit fee disclosures warrant closer scrutiny.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial professionals before making investment decisions. Lantern Pharma’s filings include forward-looking statements subject to risks and uncertainties that may cause actual results to differ materially from those projected.

View Lantern Pharma Inc. Historical chart here